logo
Boots launches memory box initiative to help people living with dementia

Boots launches memory box initiative to help people living with dementia

Yahoo26-05-2025

Boots has launched a nationwide initiative to help people with dementia.
The health and beauty retailer has created more than 1,000 multi-sensory memory boxes, which are being distributed to care homes and communities across the UK during Dementia Action Week, which runs from Monday, May 19 to Sunday, May 25.
The initiative is based on research by Professor Victoria Tischler and her colleagues from the Universities of Surrey, West London and Nottingham, which highlights the connection between smell, familiar objects and memory.
The study, conducted using the Boots Memory Boxes, found that handling familiar objects with distinctive smells and designs can provide well-being benefits for people with dementia, including improved mood, social inclusion and memory retrieval.
The memory boxes are filled with items carefully selected by the Boots Archive team, including popular toiletries and soaps, which can remind people of loved ones, and cough medicine or bath salts, which can help them remember times they cared for themselves or others.
READ: Dementia wait times in Dorset higher than national average
The boxes also feature items with familiar sounds, such as the click of an old powder compact or camera.
Many of the items in the boxes were donated by Boots team members, partners and suppliers.
Sophie Clapp, Boots company archivist, said: "With over 175 years of history, Boots is a brand that has been part of people's lives through generations.
"Through our memory box initiative, we can use our rich history and extensive archive to spark connections between those affected by dementia and their loved ones and carers over shared memories and experiences.
"It has been great to see the positive impact the Boots Memory Boxes have had through the research project with Professor Tischler and her team and to see how much the boxes have meant to the care home residents that have received them so far."
READ: 'I moved to Weymouth a year ago - It's a great place to live'
Professor Victoria Tischler, professor of behavioural science at the University of Surrey, said: "Our research showed clear connections between sensory simulation, memory and well-being.
"We built on the established connection between smell and memory to create memory boxes that use recognisable Boots products that stimulate engagement and enhance mood in those affected by dementia.
"It's really great that Boots is now rolling out its memory boxes to reach more people with dementia as well as creating a resource for their carers – a group it's so important to support. It's such a simple initiative yet it has a powerful impact that's backed up by research."
READ: Dementia-friendly screenings planned at Dorchester cinema
One care home that was among the first to receive a Boots Memory Box held an interactive session with their residents.
Lucy Atkinson, director at Church Farm Care, Nottingham, said: "During the memory box sessions we've held, I've seen the most remarkable transformation in the people who live with us here.
"People living with dementia light up when they smell something familiar from their youth, sparking memories that last beyond the session.
"One lady was flooded with happy memories seeing items she remembered from childhood, which prompted her to animatedly share stories with the group.
"The sessions have not only brought a lot of joy but also help to access memories that were otherwise lost, memories that help people to remember who they are."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

England fast bowler Brydon Carse considered getting toe amputated
England fast bowler Brydon Carse considered getting toe amputated

Associated Press

time2 hours ago

  • Associated Press

England fast bowler Brydon Carse considered getting toe amputated

LONDON (AP) — England fast bowler Brydon Carse said he considered getting a toe amputated after encountering longstanding problems because of his bowling action. The damage to his second toe on his left foot became so bad over the winter when playing for England that Carse was forced to pull out midway through its Champions Trophy campaign in Pakistan and withdraw from a lucrative deal in the Indian Premier League. The 29-year-old Carse explored every option to deal with the issue, including a drastic remedy. 'It ended up being quite a severe wound I was playing with for the majority of the winter. It got infected a couple of times,' said Carse, speaking on Thursday ahead of England's first Twenty20 against the West Indies on Friday. 'It is a bit of a running joke in the changing room, my second toe. So we came up with the thought, 'Can we just get rid of the second toe?' 'Everyone has had their opinion on my second toe. At one stage I was going to bed thinking, 'I could actually do this, I think I could get rid of my second toe.' But then the medical staff said you need it for balance so that was quickly ruled out.' England test captain Ben Stokes' late father, Ged, famously took a similar course of action in his rugby league days, removing his middle finger at the knuckle to speed up his return to action. Carse has just returned to action and was picked on Thursday in England's 14-man squad for the five-match test series against India. ___ AP cricket:

MHRA Urges Contraception With GLP-1 Weight-Loss Drugs
MHRA Urges Contraception With GLP-1 Weight-Loss Drugs

Medscape

time2 hours ago

  • Medscape

MHRA Urges Contraception With GLP-1 Weight-Loss Drugs

The Medicines and Healthcare products Regulatory Agency (MHRA) has reiterated that women using weight-loss drugs must use effective contraception, as the risks of these drugs to a foetus remain unclear. The warning follows concerns that some users in the UK may not be taking glucagon-like peptide-1 receptor agonists (GLP-1s) safely. To date, the MHRA has received more than 40 reports relating to pregnancies in women taking these medications. 'These medicines must not be taken during pregnancy, while trying to get pregnant, or during breastfeeding,' the MHRA stated. Women who become pregnant while using these drugs should stop treatment immediately and consult a healthcare professional. There is not enough safety data to determine if the drugs could harm a developing baby, the agency said. Avoid Unregulated Sellers, MHRA Warns The MHRA also warned against buying these drugs from unregulated sources such as beauty salons or via social media. 'Not only does this expose people wanting to lose weight to serious health risks, it is also against the law to sell these medicines in this way,' said Dr Alison Cave, the MHRA's chief safety officer. The agency emphasised that weight-loss drugs should not be taken without first consulting a healthcare professional. 'The only way to guarantee receiving a genuine GLP-1 medicine is to obtain it from a legitimate pharmacy,' Cave said. Pharmacies Seeing High Demand 'Community pharmacies have been experiencing unprecedented levels of interest for weight loss injections,' said Jasmine Shah, medication safety officer at the National Pharmacy Association. 'It is therefore important that regulations and guidance keep pace with this demand.' Mounjaro May Lower Effectiveness of Oral Contraceptives The MHRA noted that Mounjaro (tirzepatide) may reduce the effectiveness of oral contraceptives in people with overweight or obesity. Women taking Mounjaro should use a non-oral contraceptive method for 4 weeks after starting the drug and for 4 weeks after any dose increase. This advice applies only to Mounjaro users. Patients are also advised to be alert for signs of acute pancreatitis. Risks in Pregnancy Remain Unclear 'There is hardly any available data from human studies to be able to advise if these weight loss drugs are safe in pregnancy,' said Rebecca Reynolds, professor of metabolic medicine at the University of Edinburgh. 'The data from animal studies suggests the potential for harm with low birthweight and skeletal abnormalities, though more evidence is needed to assess if there are risks of taking these drugs in humans,' she told the Science Media Centre (SMC). Dr Bassel Wattar, consultant obstetrician and gynaecologist at Epsom and St Helier University Hospitals, supported the MHRA's warning. 'There is some data from animal studies suggesting there is a risk of malformation to the foetus — in animals falling pregnant while taking GLP-1 agonists — but data remains limited in humans,' he said. However, Dr Caroline Ovadia, senior clinical lecturer in obstetrics at the University of Edinburgh, noted to the SMC that existing human cohort studies had not shown clear evidence of harm. Online Buyers May Miss Safety Guidance Although direct evidence linking GLP-1 drugs to contraceptive failure is limited, the high number of users means even a small risk could have public health implications, experts warned. Professor Ying Cheong, consultant in reproductive medicine at the University of Southampton, speaking to the SMC, said that gastrointestinal side effects, such as vomiting and diarrhoea, could impair oral contraceptive absorption, increasing the risk of unintended pregnancy. 'Many people are buying weight loss drugs online and so may not receive this important advice about contraception,' Reynolds pointed out. 'These are not harmless lifestyle drugs,' stressed Cheong. 'The public urgently needs to understand that these medications require proper medical supervision to avoid unintended harm, particularly to reproductive health.'

GMC Updates Fitness to Practise Rules Amid PA Criticism
GMC Updates Fitness to Practise Rules Amid PA Criticism

Medscape

time4 hours ago

  • Medscape

GMC Updates Fitness to Practise Rules Amid PA Criticism

The General Medical Council (GMC) has published updated fitness to practise guidance aimed at providing greater clarity and consistency in handling concerns about medical professionals in the UK. The changes follow long-standing criticisms of the GMC's approach to fitness to practise (FtP) investigations and its promises to introduce more compassionate procedures. However, the updated guidance drew immediate criticism for treating doctors under the same regulatory framework as physician associates (PAs) and anaesthesia associates (AAs). Key Changes to Assessment Process The updates to FtP guidance provide case examiners with a framework for assessing whether concerns received by the GMC should be interpreted as meaning that a doctor may pose a risk to the public. This follows changes made last year by the regulator to investigations involving violence and dishonesty. These gave decision-makers more discretion in minor cases judged to represent a lower risk to public protection. The new guidance introduces three core questions for decision-makers when assessing whether concerns should proceed to investigation: What is the seriousness of the concern? What is the impact of relevant context? How has the doctor responded? Factors that may increase seriousness include repeat behaviour, abuse of position, or allegations involving vulnerable individuals. Decision-makers will also consider working environment, personal circumstances, and whether the professional has shown insight and remediation. Investigation Triggers Fitness to practise investigations may still be initiated for: Misconduct Poor performance Criminal conviction or caution Physical or mental ill-health affecting practice Determination by another regulatory body Insufficient knowledge of English The thresholds for FtP concerns remain unchanged, but the assessment process will be more structured. The Medical Protection Society (MPS) welcomed the GMC's efforts 'to deliver a fitness to practise process that is fairer and more compassionate'. Dr Rob Hendry, the society's medical director, told Medscape News UK : 'Finding out that fitness to practise is being called into question can have a significant impact on a doctor's mental wellbeing.' He added that the MPS had 'long called for more to be done to ensure doctors are not dragged through this stressful process unnecessarily'. Doctors' Association Raises Concerns The new guidance brings FtP decisions for doctors into line with how cases involving PAs and AAs are considered. The GMC assumed responsibility for regulation of PAs and AAs in December 2024. The move was vigorously opposed by many in the medical profession, particularly by GPs who wanted medical associates kept out of general practice altogether. The Doctors' Association UK (DAUK) appreciated the GMC's attempt to clarify its guidance but expressed concern about aligning doctor regulation with PA and AA processes. Helen Fernandes, DAUK chair, highlighted that the GMC has not set standards or scope of clinical practice for medical associates. 'If there was an issue around the clinical decision-making of a PA or AA, there are no standards against which they can be judged," she told Medscape News UK . This contrasts with doctors' clinical conduct being assessed against strict standards for many years. DAUK has expressed unease about how doctors will be held accountable for supervising PAs and AAs, noting that the GMC has attributed supervision responsibilities to anyone working with them in a team. "This guidance seems to add more confusion to an already confused picture, which we believe doesn't help our members – but more importantly, doesn't help our patients or the wider public," Fernandes said. The updated guidance is available on the GMC's website.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store